This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chu, C.
Right arrow Articles by Rastogi, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chu, C.
Right arrow Articles by Rastogi, S. C.

 Previous Article  |  Next Article 

Infect Immun. 1983 April; 40(1): 245-256
Copyright © 1983, American Society for Microbiology. All Rights Reserved.

Further Studies on the Immunogenicity of Haemophilus influenzae Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates

Chiayung Chu{dagger}, Rachel Schneerson, John B. Robbins and Suresh C. Rastogi

Division of Bacterial Products, Office of Biologics, Food and Drug Administration, Bethesda, Maryland 20205

ABSTRACT

Conjugates were prepared by carbodiimide-mediated coupling of adipic acid hydrazide derivatives of Haemophilus influenzae type b (Hib), Escherichia coli K100, and pneumococcal 6A (Pn6A) polysaccharides with tetanus toxoid (TT), as an example of a "useful" carrier, and horseshoe crab hemocyanin (HCH), as an example of a "nonsense" carrier. These conjugates were injected into NIH mice, and their serum antibody responses to the polysaccharides and proteins were characterized. As originally reported, Hib conjugates increased the immunogenicity of the capsular polysaccharide and elicited greater than the estimated protective levels of anti-Hib antibodies in most recipients after one injection and in all after the third injection (Schneerson et al., J. Exp. Med. 152:361-376, 1980). Both Hib conjugates induced similar anti-Hib responses. The K100-HCH conjugate was more immunogenic than the K100-TT conjugate and elicited anti-Hib responses similar to the Hib conjugates after the third injection. Simultaneous injection of the K100 and the Hib conjugates did not enhance the anti-Hib response. The Pn6A-TT conjugate induced low levels of anti-Hib antibodies; when injected simultaneously with the Hib conjugates, the anti-Hib response was enhanced, as all mice responded after the first injection and with higher levels of anti-Hib than observed with the Hib conjugates alone (P < 0.05). The Pn6A conjugates were not as immunogenic as the Hib conjugates. Pn6A-TT was more effective than was Pn6A-HCH; it elicited anti-Pn6A (>100 ng of antibody nitrogen per ml) in 6 of 10 mice after the third injection. The addition of the Hib-HCH conjugate to the Pn6A-TT conjugate increased the anti-Pn6A response with a higher geometric mean antibody titer, and 9 of 10 mice responded after the third injection. A preparation of diphtheria toxoid, TT, and pertussis vaccine increased the anti-Hib antibody levels after the first injection only in mice receiving Hib-TT, but not in mice receiving Hib-HCH, suggesting that additional carrier protein (TT) enhanced the anti-polysaccharide response. Simultaneous injection of Hib and Pn6A conjugates with the same or different carriers resulted in an enhanced serum antibody response to each polysaccharide. The anti-tetanus toxin response reached protective levels (>0.01 U/ml) in most mice after the first injection and in all mice after the second and third injections of TT conjugates. A progressive increase in the anti-HCH response with each additional injection was noted in animals receiving HCH conjugates. Animals receiving the diphtheria toxoid-TT-pertussis vaccine preparation responded with a greater increase in anti-carrier antibody than those receiving the conjugates alone. This method of synthesis provided conjugates capable of inducing protective levels of antibodies to both the polysaccharides and carrier proteins.

FOOTNOTES

{dagger} Visiting Fellow, National Institutes of Health Fogarty International Center, on leave from Institute of Biological Products, Shanghai, People's Republic of China.

Infect Immun. 1983 April; 40(1): 245-256
Copyright © 1983, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Casadevall, A., Fang, F. C. (2009). Important Science--It's All about the SPIN. Infect. Immun. 77: 4177-4180 [Abstract] [Full Text]  
  • Fernandez-Santana, V., Cardoso, F., Rodriguez, A., Carmenate, T., Pena, L., Valdes, Y., Hardy, E., Mawas, F., Heynngnezz, L., Rodriguez, M. C., Figueroa, I., Chang, J., Toledo, M. E., Musacchio, A., Hernandez, I., Izquierdo, M., Cosme, K., Roy, R., Verez-Bencomo, V. (2004). Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b. Infect. Immun. 72: 7115-7123 [Abstract] [Full Text]  
  • Verez-Bencomo, V., Fernandez-Santana, V., Hardy, E., Toledo, M. E., Rodriguez, M. C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdes, Y., Cosme, K., Deler, M. L., Montane, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Torano, G., Sosa, I., Hernandez, I., Martinez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, F., Campa, C., Diaz, M., Roy, R. (2004). A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b. Science 305: 522-525 [Abstract] [Full Text]  
  • Jin, Z., Chu, C., Robbins, J. B., Schneerson, R. (2003). Preparation and Characterization of Group A Meningococcal Capsular Polysaccharide Conjugates and Evaluation of Their Immunogenicity in Mice. Infect. Immun. 71: 5115-5120 [Abstract] [Full Text]  
  • Goetsch, L., Haeuw, J. F., Champion, T., Lacheny, C., N'Guyen, T., Beck, A., Corvaia, N. (2003). Identification of B- and T-Cell Epitopes of BB, a Carrier Protein Derived from the G Protein of Streptococcus Strain G148. CVI 10: 125-132 [Abstract] [Full Text]  
  • Passwell, J. H., Harlev, E., Ashkenazi, S., Chu, C., Miron, D., Ramon, R., Farzan, N., Shiloach, J., Bryla, D. A., Majadly, F., Roberson, R., Robbins, J. B., Schneerson, R. (2001). Safety and Immunogenicity of Improved Shigella O-Specific Polysaccharide-Protein Conjugate Vaccines in Adults in Israel. Infect. Immun. 69: 1351-1357 [Abstract] [Full Text]  
  • Shen, X., Lagergard, T., Yang, Y., Lindblad, M., Fredriksson, M., Holmgren, J. (2001). Group B Streptococcus Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccines Prepared by Different Methods for Intranasal Immunization. Infect. Immun. 69: 297-306 [Abstract] [Full Text]  
  • Peltola, H. (2000). Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates. Clin. Microbiol. Rev. 13: 302-317 [Abstract] [Full Text]  
  • Rauly, I., Goetsch, L., Haeuw, J.-F., Tardieux, C., Baussant, T., Bonnefoy, J.-Y., Corvaia, N. (1999). Carrier Properties of a Protein Derived from Outer Membrane Protein A of Klebsiella pneumoniae. Infect. Immun. 67: 5547-5551 [Abstract] [Full Text]  
  • obbins, J. B., Schneerson, R., Porter, A., Smith, D. H. (1996). Prevention of Systemic Infections, Especially Meningitis, Caused by Haemophilus influenzae Type b: Impact on Public Health and Implications for Other Polysaccharide-Based. JAMA 276: 1181-1185 [Abstract]  
  • Kayhty, H., Eskola, J., Peltola, H., Ronnberg, P-R., Kela, E., Karanko, V., Saarinen, L. (1991). Antibody Responses to Four Haemophilus influenzae Type b Conjugate Vaccines. Arch Pediatr Adolesc Med 145: 223-227 [Abstract]  
  • Paton, J. C., Toogood, I. R., Cockington, R. A., Hansman, D. (1986). Antibody Response to Pneumococcal Vaccine in Children Aged 5 to 15 Years. Arch Pediatr Adolesc Med 140: 135-138 [Abstract]  
  • Cochi, S. L., Broome, C. V., Hightower, A. W. (1985). Immunization of US Children With Hemophilus influenzae Type b Polysaccharide Vaccine: A Cost-effectiveness Model of Strategy Assessment. JAMA 253: 521-529 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»